ArticleFrontiers in oncology2025
Integrating quantitative DCE-MRI parameters and radiomic features for improved IDH mutation prediction in gliomas.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Application of a multimodal MRI model integrating radiomics and habitat features for predicting glioma pathology and prognosis.BMC medical imaging · 2026Article
- Fully automated Res3DNet model to predict IDH mutation of gliomas from whole-brain MRI free of tumor segmentation.iScience · 2026Article
- Improving radiomics-based isocitrate dehydrogenase 1 prediction in glioma patients using semi-supervised machine learning models.BMC medical imaging · 2025Article
- Predicting glioma histo-molecular diagnosis and prognosis: preoperative dynamic contrast-enhanced magnetic resonance imaging insights.Quantitative imaging in medicine and surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To develop and validate a multiparametric prognostic model, incorporating dynamic contrast-enhanced (DCE) quantitative parameters and multi-modality radiomic features, for the accurate identification of isocitrate dehydrogenase 1 (IDH1) mutation status from glioma patients. Methods: A total of 152 glioma patient data with confirmed IDH1 mutation status were retrospectively collected. A segmentation neural network was used to measure MRI quantitative parameters compared with the empirically oriented ROI selection. Radiomic features, extracted from conventional MR images (T1CE, T2W, and ADC), and DCE quantitative parameter images were combined with MRI quantitative parameters in our research to predict IDH1 mutation status. We constructed and analyzed Clinical Models 1-2 (corresponding to manual and automatic MRI quantitative parameters), Radiomic Feature Models 1-3 (corresponding to structural MRI, DCE, and multi-modality respectively), and a Multivariable Combined Model. We tried different usual classifiers and selected logistic regression according to AUC. Fivefold cross-validation was applied for validation. Results: The Multivariable Combined Model showed the best prediction performance (AUC, 0.915; 95% CI: 0.87, 0.96) in the validation cohort. The Multivariable Combined Model performed better than Clinical Model 1 and Radiomic Feature Model 1 (DeLong all p < 0.05), and Radiomic Feature Model 3 performed better than Radiomic Feature Model 1 (DeLong p < 0.05). Conclusions: Compared with the conventional MRI Radiomics and Clinical Models, the Multivariable Combined Model, mainly based on DCE quantitative parameters and multi-modality Radiomics features, is the most promising and deserves attention in the current study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.